Strong Increase in Moxifloxacin Resistance Rate among Multidrug-Resistant Mycobacterium tuberculosis Isolates in China, 2007 to 2013-Reference-Cited by-同舟云学术

Strong Increase in Moxifloxacin Resistance Rate among Multidrug-Resistant Mycobacterium tuberculosis Isolates in China, 2007 to 2013

Published:2021-12-22 Issue:3 Volume:9 Page:
ISSN:2165-0497
Container-title:Microbiology Spectrum
language:en
Short-container-title:Microbiol Spectr

Author:

Xia Hui¹,Zheng Yang¹,Liu Dongxin²,Wang Shengfen¹,He WenCong¹,Zhao Bing¹,Song Yuanyuan¹,Ou Xichao¹,Zhou Yang¹,van den Hof Susan³,Cobelens Frank⁴,Zhao YanLin¹^ORCID

Affiliation:

1. National Tuberculosis Reference Laboratory, National Center for Tuberculosis Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China

2. Institute of Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People’s Hospital, Shenzhen, China

3. National Institute of Public Health and the Environment, Centre for Infectious Disease Epidemiology and Surveillance, Bilthoven, The Netherlands

4. Department of Global Health and Amsterdam Institute for Global Health and Development, Amsterdam University Medical Centers, Amsterdam, The Netherlands

Abstract

China is one of the high-burden countries for multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB). Moxifloxacin is one of the critical antituberculosis drugs for MDR/RR-TB treatment.

Funder

National Science and Technology Major Project of China

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Cell Biology,Microbiology (medical),Genetics,General Immunology and Microbiology,Ecology,Physiology

Link

https://journals.asm.org/doi/pdf/10.1128/Spectrum.00409-21

Reference47 articles.

1. World Health Organization. 2020. Global tuberculosis report 2020. World Health Organization, Geneva, Switzerland.

2. World Health Organization. 2020. WHO consolidated guidelines on tuberculosis. Module 4: treatment – drug-resistant tuberculosis treatment. World Health Organization, Geneva, Switzerland.

3. National Survey of Drug-Resistant Tuberculosis in China

4. Concordance of Mycobacterium tuberculosis fluoroquinolone resistance testing: implications for treatment

5. Stepwise Decrease in Moxifloxacin Susceptibility amongst Clinical Isolates of Multidrug-ResistantMycobacterium tuberculosis:Correlation with Ofloxacin Susceptibility

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Transmission of fluoroquinolones resistance among multidrug-resistant tuberculosis in Shanghai, China: a retrospective population-based genomic epidemiology study;Emerging Microbes & Infections;2024-01-22

2. Drug recommendation for optimization on treatment outcome for MDR/RR-TB based on a multi-center, large scale, retrospective cohort study in China;Expert Review of Anti-infective Therapy;2024-01-22

3. Comparison of the in vitro antibacterial activity of ofloxacin, levofloxacin, moxifloxacin, sitafloxacin, finafloxacin, and delafloxacin against Mycobacterium tuberculosis strains isolated in China;Heliyon;2023-11

4. Insight into the drug-resistant characteristics and genetic diversity of multidrug-resistant Mycobacterium tuberculosis in China;Microbiology Spectrum;2023-10-17

5. Evaluation of genetic mutations associated with phenotypic resistance to fluoroquinolones, bedaquiline, and linezolid in clinical Mycobacterium tuberculosis: A systematic review and meta-analysis;Journal of Global Antimicrobial Resistance;2023-09